MDRNA, the Bothell, WA-based developer of RNA interference drugs, said today it has agreed to license part of its technology for a one-time, non-refundable execution fee from Swiss drug giant Roche. The deal is non-exclusive to Roche, although MDRNA said it will provide enough capital for the company to pursue other non-exclusive licensing and financing opportunities.Shares of MDRNA (NASDAQ: [[ticker:MRNA]]) climbed by more than 30 percent, to 33 cents, after the announcement. The company has been running low on cash.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
